Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
allergan
4
×
biotech
clinical trials
eli lilly
fda
life sciences
4
×
national blog main
national top stories
abbvie
amgen
boston blog main
boston top stories
national
new york blog main
biohaven
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
indiana blog main
indiana top stories
marc goodman
migraine
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
svb leerink
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
10x genomics
alder biopharmaceutical
What
fda
4
×
won
class
drug
drugs
migraine
new
treatment
adults
alkermes
allergan
antipsychotic
approval
approved
arguments
august
benefits
big
bio
biotech
busy
caveats
commercialized
commonly
companies
competitors
days
decades
decisions
designed
devices
effect
favor
gain
legacy
make
medicine
medicines
meeting
monday
Language
unset
Current search:
allergan
×
fda
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments